Rachel Orler Reid
Research Subjects
Rachel Orler Reid has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cheryl L. Damberg
Center of Excellence on Health System Performance, RAND Corporation , Santa Monica, CA 90401
3 shared publications Cheryl L. Damberg
RAND Corporation, Santa Monica, California and Boston, Massachusetts
2 shared publicationsA. Mark Fendrick
Department of Internal Medicine, University of Michigan, Ann Arbor, USA
1 shared publication- Arindam Debbarma
Walmart Inc , Bentonville, AR 72712
1 shared publication Ashlyn K. Tom
RAND Corporation, Santa Monica, California and Boston, Massachusetts
1 shared publication- Brendan Rabideau
Analysis Group, Los Angeles, USA
1 shared publication
Latest Publications
- Open Access
- 3 March 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (4) , qxaf042
Medicare Part D insulin coverage: formulary strategies amid policy headwinds
In recent years, multiple insulin-related policies took effect for Medicare Part D plans, including the Part D Senior Savings Model test (2021–2023) and the 2022 Inflation Reduction Act, provisions of which were implemented between 2023 and 2025. These policies created a variety of financial incentives for plans that may influence insulin formulary design in Part D, potentially affecting beneficiary access to insulin. For example, while limiting cost-sharing lowers out-of-pocket costs for beneficiaries, it may also reduce plans' ability to use tiering to steer beneficiaries toward preferred insulins. Using Part D formulary files from 2020–2025 we examined plan insulin coverage separately for Medicare Advantage Prescription Drug Plans and stand-alone Prescription Drug Plans. We found that plans are moving insulins to a single tier but not broadly changing their utilization management tool strategies. Combination agents (insulins paired with GLP-1s) account for the majority of insulins with quantity limits, and concentrated insulins account for the bulk of insulins with prior authorization requirements. This study demonstrates strategic adjustments that insurers may be making in response to policy changes; ongoing study will be needed to monitor access to and spending on insulin in Medicare as the market and policy context continue to evolve.
- 3 March 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (4) , qxaf042
Open AccessMedicare Part D insulin coverage: formulary strategies amid policy headwinds
In recent years, multiple insulin-related policies took effect for Medicare Part D plans, including the Part D Senior Savings Model test (2021–2023) and the 2022 Inflation Reduction Act, provisions of which were implemented between 2023 and 2025. These policies created a variety of financial incentives for plans that may influence insulin formulary design in Part D, potentially affecting beneficiary access to insulin. For example, while limiting cost-sharing lowers out-of-pocket costs for beneficiaries, it may also reduce plans' ability to use tiering to steer beneficiaries toward preferred insulins. Using Part D formulary files from 2020–2025 we examined plan insulin coverage separately for Medicare Advantage Prescription Drug Plans and stand-alone Prescription Drug Plans. We found that plans are moving insulins to a single tier but not broadly changing their utilization management tool strategies. Combination agents (insulins paired with GLP-1s) account for the majority of insulins with quantity limits, and concentrated insulins account for the bulk of insulins with prior authorization requirements. This study demonstrates strategic adjustments that insurers may be making in response to policy changes; ongoing study will be needed to monitor access to and spending on insulin in Medicare as the market and policy context continue to evolve.
- Open Access
- 28 October 2024
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 2 (11) , qxae135
Medicare transitional care management services’ association with readmissions and mortality
In 2013, the Centers for Medicare and Medicaid Services (CMS) introduced codes to reimburse outpatient providers for post-discharge transitional care management (TCM). Understanding the implications of TCM reimbursement on outcomes is crucial for evaluating CMS's investment and guiding future policy. We analyzed the association between physician organization (PO) TCM code use and post-discharge readmissions and mortality using 100% fee-for-service Medicare claims. Using a difference-in-differences approach we compared 1131 “high-TCM” POs (top quartile of TCM code use from 2015–2017) to 1133 “low-TCM” POs (bottom quartile) from before (2012) and after (2015–2017) TCM code implementation, controlling for PO and beneficiary attributes and readmission risk. TCM code use was associated with decreased 30- and 90-day readmissions (−0.31 [95%CI: −0.52, −0.09] and −0.42 [95% CI: −0.71, −0.14] percentage points, respectively), but no significant difference in mortality. Year-by-year, 2017 saw greatest readmission reduction, with a slight mortality reduction in that year only. Readmission reductions were greatest in POs not affiliated with health systems, Accountable Care Organizations (ACOs), or academic medical centers, and least in those with fewer primary care physicians. Narrow, indirect interventions like fee-for-service TCM billing code reimbursement may have limited potential to improve post-discharge outcomes overall. However, small independent practices may derive somewhat greater benefit from this support for post-discharge care.
- 28 October 2024
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 2 (11) , qxae135
Open AccessMedicare transitional care management services’ association with readmissions and mortality
In 2013, the Centers for Medicare and Medicaid Services (CMS) introduced codes to reimburse outpatient providers for post-discharge transitional care management (TCM). Understanding the implications of TCM reimbursement on outcomes is crucial for evaluating CMS's investment and guiding future policy. We analyzed the association between physician organization (PO) TCM code use and post-discharge readmissions and mortality using 100% fee-for-service Medicare claims. Using a difference-in-differences approach we compared 1131 “high-TCM” POs (top quartile of TCM code use from 2015–2017) to 1133 “low-TCM” POs (bottom quartile) from before (2012) and after (2015–2017) TCM code implementation, controlling for PO and beneficiary attributes and readmission risk. TCM code use was associated with decreased 30- and 90-day readmissions (−0.31 [95%CI: −0.52, −0.09] and −0.42 [95% CI: −0.71, −0.14] percentage points, respectively), but no significant difference in mortality. Year-by-year, 2017 saw greatest readmission reduction, with a slight mortality reduction in that year only. Readmission reductions were greatest in POs not affiliated with health systems, Accountable Care Organizations (ACOs), or academic medical centers, and least in those with fewer primary care physicians. Narrow, indirect interventions like fee-for-service TCM billing code reimbursement may have limited potential to improve post-discharge outcomes overall. However, small independent practices may derive somewhat greater benefit from this support for post-discharge care.
- Open Access
- 7 December 2023
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 1 (6) , qxad065
Barriers primary care clinic leaders face to improving value in a consumer choice health plan design
Primary care clinics are a frequent focus of policy initiatives to improve the value of health care; yet, it is unclear whether they have the ability or incentive to take on the additional tasks that these initiatives ask of them. This paper reports on a qualitative study assessing barriers that clinic leaders face to reducing cost within a tiered cost-sharing commercial health insurance benefit design that gives both consumers and clinics a strong incentive to reduce cost. We conducted semi-structured interviews of clinical and operational leaders at a diverse set of 12 Minnesota primary care clinics and identified 6 barriers: insufficient information on drivers of cost; clinics controlling a portion of spending; patient preference for higher cost specialists; administrative challenges; limited resources; and misalignment of incentives. We discuss approaches to reducing these barriers and opportunities to implement them.
- 7 December 2023
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 1 (6) , qxad065
Open AccessBarriers primary care clinic leaders face to improving value in a consumer choice health plan design
Primary care clinics are a frequent focus of policy initiatives to improve the value of health care; yet, it is unclear whether they have the ability or incentive to take on the additional tasks that these initiatives ask of them. This paper reports on a qualitative study assessing barriers that clinic leaders face to reducing cost within a tiered cost-sharing commercial health insurance benefit design that gives both consumers and clinics a strong incentive to reduce cost. We conducted semi-structured interviews of clinical and operational leaders at a diverse set of 12 Minnesota primary care clinics and identified 6 barriers: insufficient information on drivers of cost; clinics controlling a portion of spending; patient preference for higher cost specialists; administrative challenges; limited resources; and misalignment of incentives. We discuss approaches to reducing these barriers and opportunities to implement them.
- Open Access
- 28 January 2022
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 3 (1) , e214634
Physician Compensation Arrangements and Financial Performance Incentives in US Health Systems
Since passage of the US Affordable Care Act, public and private payers in the US have undertaken various payment reforms to improve quality and reduce spending. Alternative payment models (APMs) and value-based payment (VBP) seek to redirect the health system’s focus toward producing value instead of volume.1-8 Whether it is a response to value-oriented payment models or not,9-11 during the same period, health systems and their employment of physicians have grown.12-16
- 28 January 2022
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 3 (1) , e214634
Open AccessPhysician Compensation Arrangements and Financial Performance Incentives in US Health Systems
Since passage of the US Affordable Care Act, public and private payers in the US have undertaken various payment reforms to improve quality and reduce spending. Alternative payment models (APMs) and value-based payment (VBP) seek to redirect the health system’s focus toward producing value instead of volume.1-8 Whether it is a response to value-oriented payment models or not,9-11 during the same period, health systems and their employment of physicians have grown.12-16
- 9 January 2021
- Published by Elsevier in Journal of Health Economics
- Vol. 76, 102424
Effects of employer-offered high-deductible plans on low-value spending in the privately insured population
- 9 January 2021
- Published by Elsevier in Journal of Health Economics
- Vol. 76, 102424
Effects of employer-offered high-deductible plans on low-value spending in the privately insured population
- Open Access
- 20 August 2020
- Published by Wiley in Health Services Research
- Vol. 55 (S1) , 126
Where Are We in the Transition to Value‐Based Payments?: Findings from a Study on Health System Physician Compensation Arrangements and Financial Incentives for Performance
Policymakers continue to set aggressive targets for alternative payment model engagement, aiming to spur a transition from volume‐ to value‐oriented payment to drive performance improvements. However, the extent to which payments to providers have transitioned to paying for value is unclear. Given their greater ability to enter into payment arrangements with financial risk, health systems may be particularly well‐positioned to reflect value‐orientation in their physician compensation and incentives. In this study, we sought to characterize frontline physician compensation and financial incentives for health system affiliated physician organizations (POs).
- 20 August 2020
- Published by Wiley in Health Services Research
- Vol. 55 (S1) , 126
Open AccessWhere Are We in the Transition to Value‐Based Payments?: Findings from a Study on Health System Physician Compensation Arrangements and Financial Incentives for Performance
Policymakers continue to set aggressive targets for alternative payment model engagement, aiming to spur a transition from volume‐ to value‐oriented payment to drive performance improvements. However, the extent to which payments to providers have transitioned to paying for value is unclear. Given their greater ability to enter into payment arrangements with financial risk, health systems may be particularly well‐positioned to reflect value‐orientation in their physician compensation and incentives. In this study, we sought to characterize frontline physician compensation and financial incentives for health system affiliated physician organizations (POs).
- 29 July 2020
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (8) , 2478-2482
Waste in the Medicare Program: a National Cross-Sectional Analysis of 2017 Low-Value Service Use and Spending
- 29 July 2020
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (8) , 2478-2482
Waste in the Medicare Program: a National Cross-Sectional Analysis of 2017 Low-Value Service Use and Spending
- 28 April 2020
- Published by BMJ in BMJ Quality & Safety
- Vol. 30 (2) , 167-172
Does removing financial incentives lead to declines in performance? A controlled interrupted time series analysis of Medicare Advantage Star Ratings programme performance
The Star Ratings incorporate measures from various sources (eg, Healthcare Effectiveness Data and Information Set (HEDIS), Consumer Assessment of Healthcare Providers and Systems (CAHPS), Health Outcomes Survey (HOS)). CMS has added and removed Star Ratings measures over time; removed measures are still monitored and published on cms.gov, but no longer contribute to bonus payments to plans and are not publicly reported to consumers on the Medicare Plan Finder website. Thus, both financial and non-financial incentives are removed when measures are removed from the Star Ratings methodology.
- 28 April 2020
- Published by BMJ in BMJ Quality & Safety
- Vol. 30 (2) , 167-172
Does removing financial incentives lead to declines in performance? A controlled interrupted time series analysis of Medicare Advantage Star Ratings programme performance
The Star Ratings incorporate measures from various sources (eg, Healthcare Effectiveness Data and Information Set (HEDIS), Consumer Assessment of Healthcare Providers and Systems (CAHPS), Health Outcomes Survey (HOS)). CMS has added and removed Star Ratings measures over time; removed measures are still monitored and published on cms.gov, but no longer contribute to bonus payments to plans and are not publicly reported to consumers on the Medicare Plan Finder website. Thus, both financial and non-financial incentives are removed when measures are removed from the Star Ratings methodology.
- 1 January 2020
- Published by Rand Corporation
Advancing the Development of a Framework to Capture Non–Fee-for-Service Health Care Spending for Primary Care
This report describes work conducted to understand what non-fee-for-service payment data are being collected by states and other stakeholders to support more complete measurement of primary care spending as a proportion of total health care spending.
- 1 January 2020
- Published by Rand Corporation
Advancing the Development of a Framework to Capture Non–Fee-for-Service Health Care Spending for Primary Care
This report describes work conducted to understand what non-fee-for-service payment data are being collected by states and other stakeholders to support more complete measurement of primary care spending as a proportion of total health care spending.